Lantheus Holdings, Inc. $LNTH Shares Sold by LSV Asset Management

LSV Asset Management reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 23.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 283,800 shares of the medical equipment provider’s stock after selling 86,800 shares during the quarter. LSV Asset Management’s holdings in Lantheus were worth $23,232,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ontario Teachers Pension Plan Board lifted its stake in shares of Lantheus by 6.5% during the second quarter. Ontario Teachers Pension Plan Board now owns 18,910 shares of the medical equipment provider’s stock worth $1,548,000 after purchasing an additional 1,151 shares in the last quarter. Intech Investment Management LLC increased its holdings in Lantheus by 22.7% in the second quarter. Intech Investment Management LLC now owns 97,076 shares of the medical equipment provider’s stock valued at $7,947,000 after buying an additional 17,948 shares during the last quarter. Cetera Investment Advisers raised its position in shares of Lantheus by 19.7% during the 2nd quarter. Cetera Investment Advisers now owns 33,943 shares of the medical equipment provider’s stock valued at $2,779,000 after acquiring an additional 5,581 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Lantheus by 7.0% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,776 shares of the medical equipment provider’s stock worth $1,455,000 after purchasing an additional 1,156 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in Lantheus by 2.9% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,274 shares of the medical equipment provider’s stock worth $1,250,000 after purchasing an additional 432 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LNTH shares. Mizuho reduced their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. JMP Securities cut their target price on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. B. Riley dropped their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Finally, Truist Financial restated a “hold” rating and set a $61.00 price objective (down previously from $63.00) on shares of Lantheus in a research report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $74.17.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $53.50 on Wednesday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The company has a market cap of $3.55 billion, a PE ratio of 14.23 and a beta of 0.04. The stock has a 50 day simple moving average of $53.85 and a 200-day simple moving average of $65.73. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million for the quarter. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.